hero image

A potential breakthrough in aiding e-cigarette users to quit vaping is on the horizon with the possible FDA approval of a new drug. Scientists from Massachusetts General Hospital have discovered that cytisinicline, derived from plants, exhibits significant potential in reducing the desire to vape. Previously effective in assisting smokers to quit traditional cigarettes, cytisinicline now offers hope for addressing vaping addiction.

Cytisinicline likely to help vaping users quit vaping

The study highlights that 11 million American adults use e-cigarettes for nicotine vaping, with approximately half expressing a desire to quit. Researchers emphasize the persistent challenge of nicotine addiction despite users’ intentions to quit.

A recent study published in JAMA Internal Medicine conducted a double-blind randomized clinical trial with 160 adults who vaped but did not smoke cigarettes. Over 12 weeks, participants were given either cytisinicline or a harmless placebo in pill form. Results indicate that those using cytisinicline were over twice as likely to quit vaping by week nine compared to those on placebos (31.8% vs. 15.1%). Additionally, participants experienced minimal side effects from the plant-based drug.

Lead author Nancy A. Rigotti, director of Massachusetts General Hospital’s Tobacco Research and Treatment Center and a Harvard Medical School professor, notes that the FDA hasn’t sanctioned any medication for vaping cessation in the US. Rigotti suggests that cytisinicline could potentially address this need and aid adult vapers in quitting e-cigarettes.

Why is Cytisinicline promising in vaping cessation?

Cytisinicline shows promise as a medication to help people quit vaping and smoking due to its ability to bind to nicotine receptors in the brain cells of patients. This makes it potentially effective for both smokers and vapers, as both nicotine sources are targeted.

However, further research is needed to confirm these findings in larger trials with longer follow-up periods. Despite its potential, FDA approval for cytisinicline as an anti-smoking and vaping medication may still be pending.

It is important to note that creating a novel medication like Cytisinicline involves a meticulous and intricate journey that may span numerous years. This journey adheres to stringent regulations aimed at guaranteeing the safety and efficacy of the pharmaceutical product.